tirzepatide to semaglutide vs Tirzepatide: Compare Diabetes Medications Tirzepatide Outperforms Semaglutide in Blood

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

When combined with lifestyle modifications and under proper medical supervision, it represents one of the most effective pharmaceutical interventions currently available for weight management

GI side effects like nausea or constipation affect about 30% of users initially, but resolve within 24 weeks for most people and can be managed with dose adjustment and dietary fiber

doi: 10.1038/s41586-024-07469-y

7.4 Drugs Affecting Glucose Metabolism The following are examples of medications that may increase the susceptibility to hypoglycemia when administered with SYMLIN: anti-diabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, salicylates, somatostatin analogs, and sulfonamide antibiotics